摘要
目的对维药骆驼刺Alhagi sparsifolia水溶性化学成分进行研究。方法采用多种色谱技术进行分离纯化,通过理化性质、波谱数据和X单晶衍射鉴定化合物结构,测试各化合物对人宫颈癌HeLa细胞的细胞毒性。结果从骆驼刺地上部分分离得到21个水溶性化合物,分别鉴定为毒豆甲酮(1)、毒豆乙酮(2)、callyspongidipeptideA(3)、环(脯氨酸-亮氨酸)(4)、对羟基苯甲醇(5)、D-脯氨酸-D-缬氨酸(6)、环(脯氨酸-亮氨酸)二肽(7)、布卢姆醇A(8)、(3S,4R)-3,4-二羟基-3-甲基二氢呋喃-2(3H)-酮(9)、isololiolide(10)、dehydrovomifoliol(11)、N-苯乙基甲酰胺(12)、3-hydroxy-β-damascone(13)、3,4-二羟基-3-甲基二氢呋喃-2(3H)-酮(14)、环(丙氨酸-脯氨酸)(15)、脯氨酸(16)、布卢姆醇B(17)、蚱蜢酮(18)、N-(对羟基苯乙基)甲酰胺(19)、N-乙酰基酪胺(20)、(+)-丁香脂素-O-β-D-葡萄糖苷(21);并对化合物1~21进行了抗宫颈癌活性筛选。结论化合物1~7、9~20为首次从骆驼刺属植物中分离得到,且化合物4、7、15表现出潜在的抗肿瘤活性,半数抑制浓度(median inhibition concentration,IC_(50))分别为(29.09±0.99)、(31.51±1.89)、(28.25±0.65)μmol/L。
Objective To study the water soluble chemical constituents of Alhagi sparsifolia.Methods A variety of chromatographic techniques were used to separate and purify,and the structure of the compounds was identified by physicochemical properties,spectral data and X-single crystal diffraction,and the cytotoxicity of each compound to HeLa cells was tested.Results Twenty-one water-soluble compounds were isolated from the above-ground parts of A.sparsifolia after the process of extraction and were identified as drummondone A(1),drummondone B(2),callyspongidipeptideA(3),cyclo(Pro-Leu)(4),4-(hydroxymethyl)phenol(5),cyclo(D)-Pro-(D)-Val(6),cyclo(L-pro-L-Leu)(7),blumenol A(8),(3S,4R)-3,4-dihydroxy-3-methyldihydrofuran-2(3H)-one(9),Isololiolide(10),dehydrovomifoliol(11),N-phenethylformamide(12),3-hydroxy-β-damascone(13),3,4-dihydroxy-3-methyldihydrofuran-2(3H)-one(14),cyclo(L-Pro-L-Ala)(15),proline(16),blumenol B(17),grasshopper ketone(18),N-(p-hydroxyphenethyl)(19),N-acetyltyramine(20),(+)-syringaresinol O-β-D-glucopyranoside(21),and compounds 1―21 were screened for anti-cervical cancer activity.Conclusion Compounds 1—7,9—20 were the first known compounds within the genus,and compounds 4,7 and 15 showed potential antitumor activity with median inhibition concentration(IC_(50))of(29.09±0.99),(31.51±1.89)and(28.25±0.65)μmol/L,respectively.
作者
鲍爽
宋海龙
热依兰木·买赛地
凯撒·苏来曼
马国需
张晶
石磊岭
韩莉莉
BAO Shuang;SONG Hailong;Reyilanmu-Maisaidi;Kaisa·Sulaiman;MA Guoxu;ZHANG Jing;SHILeiling;HAN Lili(College of Chinese Medicine Material,Jilin Agricultural University,Changchun 130118,China;Department of Gynecology,The People's Hospital of Xinjiang Uyghur Autonomous Region,Urumqi 830001,China;Xinjiang Institute of Chinese and Ethnic Medicine,Urumqi 830002,China;Institute of Medicinal Plant Development,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100193,China)
出处
《中草药》
CAS
CSCD
北大核心
2024年第17期5777-5784,共8页
Chinese Traditional and Herbal Drugs
基金
新疆维吾尔自治区重点研发计划项目(2022B03018-4)。